The safety and pharmacokinetics of metformin in patients with chronic liver disease.

Felicity C SmithSophie L StockerThomas BergJane E CarlandShaun S KumarZhixin LiuJerry R GreenfieldHannah E BraithwaiteTim S ChengGarry G GrahamKenneth M WilliamsRichard Osborne Day

Published in: Alimentary pharmacology & therapeutics (2020)

The pharmacokinetics of metformin are not altered sufficiently in CLD patients to raise concerns regarding unsafe concentrations of metformin. There were no unsafe plasma lactate concentrations observed in CLD patients receiving metformin (ACTRN12619001292167; ACTRN12619001348145).

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors